NCT05423197View on ClinicalTrials.gov

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Head-and-neck Squamous Cell Carcinoma
Interventions
DRUG

89Zr-panitumumab IV

Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions

DRUG

Panitumumab

Panitumumab 30mg will be given orally

Trial Locations (1)

94305

Stanford Cancer Institute, San Francisco

All Listed Sponsors
lead

Stanford University

OTHER